Blood test for leftover cancer after prostate surgery in high-risk prostate cancer
Studies a blood test for tumor DNA after prostate removal in high-risk prostate cancer.
Plain-language title generated from the registry record
Registry title: Detection of Minimal Residual Disease Post-prostatectomy
Key facts
- Where
- Nijmegen, NetherlandsSee the site
Where in Netherlands
- Prosper Prostate Cancer ClinicsNijmegen, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Radboud University Medical Center
- Trial code
- NCT07334275
- Record updated
- 12 January 2026
- Original description
The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.Read full original descriptionShow less
Pilot Study for the Detection of Minimal Residual Disease Post-prostatectomy and Early Disease Recurrence in Circulating Tumor DNA to Guide Future Adjuvant Therapy in High-risk Prostate Cancer Patients (MiRaDE)
The clinical objective for this pilot study is to determine whether minimal residual disease (MRD) detection in high-risk prostate cancer, utilizing a custom-made prostate-specific circulating tumor DNA (ctDNA) panel, may lead to more optimal prediction of disease recurrence following radical prostatectomy.
Inclusion: Male aged 18 years or older; High-risk prostate cancer, defined as:; High-risk localized prostate cancer, with PSA level >20 ng/mL, Gleason score 8-10 (ISUP grade 4/5) at prostate biopsies, or iT3a (based on multi-parametric MRI of the prostate); or; High-risk locally advanced prostate cancer, having any PSA level, any Gleason score/ISUP grade, iT3b-4 (based on multi-parametric MRI of the prostate) or iN1 (based on PSMA PET/CT imaging); Scheduled for robot-assisted radical prostatectomy; Willingness to consent to both patient information sheets regarding tissue and liquid biobanking.
Exclusion: Relevant contra-indications that may limit clinical follow-up or blood collection, as assessed by the including physician.